IRAK
Interleukin-1 receptor associated kinase; IL-1R associated kinase
Interleukin-1 receptor-associated kinases (IRAKs), are serine/threonine kinases, play critical roles in initiating innate immune responses against foreign pathogens and other types of dangers through their role in Toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) mediated signaling pathways. The four different IRAK-like molecules have been identified: two active kinases, IRAK-1 and IRAK-4, and two inactive kinases, IRAK-2 and IRAK-M. All IRAKs mediate activation of nuclear factor-kappaB (NF-κB) and mitogen-activated protein kinase (MAPK) pathways.
Toll-like receptors transduce their signals through the adaptor molecule MyD88 and members of the IL-1R-associated kinase family (IRAK-1, 2, M and 4). IRAK-1 and IRAK-2, known to form Myddosomes with MyD88-IRAK-4, mediate TLR7-induced TAK1-dependent NF-κB activation. IRAK-M is known to function as a negative regulator that prevents the dissociation of IRAKs from MyD88, thereby inhibiting downstream signalling.
IRAK Isoform Specific Products
All Product Categories
-
IRAK Related Products (159)
Related Products (159)
-
Antibodies (5)
-
IRAK Isoform Comparison
-
PROTAC IRAK4 degrader-8
0 ImagesPROTAC IRAK4 degrader-8 (Compound 2) is a PROTAC degrader that targets IRAK4 by recruiting cereblon. PROTAC IRAK4 degrader-8 inhibits IRAK4 kinase activity with an IC50 of 15.5 nM. PROTAC IRAK4 degrader-8 suppresses IL-6 production in immune cells. PROTAC IRAK4 degrader-8 can be used in the research of inflammatory diseases, immune diseases and cancers.
-
IRAK4-IN-22
0 ImagesIRAK4-IN-22 (compound 18) is an orally active, potent and selective IRAK4 inhibitor with IC50 values of 3 and 17 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC50=0.10 µM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis.
-
APH02174 hemiformic
0 ImagesCat. No.: HY-174455AAPH02174 hemiformic is an orally effective and selective IRAK4 PROTAC degrader with a DC50 of 4.01 nM in THP-1 cells. APH02174 hemiformic inhibits LPS (HY-D1056)-induced IL-6 release by degrading IRAK4 and blocking TLR/IL-1R downstream signaling. APH02174 hemiformic exhibits favorable anti-inflammatory activity in both Imiquimod (HY-B0180)-induced psoriasis-like skin inflammation and collagen-induced arthritis models. APH02174 hemiformic is useful for research on inflammatory diseases such as psoriasis and rheumatoid arthritis.
-
KT-474 hydrochloride
0 ImagesSynonyms: KYM-001 hydrochloride; PROTAC IRAK4 degrader-7 hydrochloride
-
APH02174
0 ImagesAPH02174 is an orally effective and selective IRAK4 PROTAC degrader with a DC50 of 4.01 nM in THP-1 cells. APH02174 inhibits LPS (HY-D1056)-induced IL-6 release by degrading IRAK4 and blocking TLR/IL-1R downstream signaling. APH02174 exhibits favorable anti-inflammatory activity in both Imiquimod (HY-B0180)-induced psoriasis-like skin inflammation and collagen-induced arthritis models. APH02174 is useful for research on inflammatory diseases such as psoriasis and rheumatoid arthritis.
-
IRAK1/4/pan-FLT3 Kinase-IN-1 hydrochloride
0 ImagesCat. No.: HY-159953APurity: 98.46%
-
UR241-2
0 ImagesUR241-2 is an IRAK4 inhibitor. UR241-2 suppresses IL-1–induced IRAK1/4 signaling, NF-κβ activation, and phosphorylation of p65 and p38. UR241-2 selectively inhibits leukemia stem cell clonogenicity. UR241-2 can serve as a ligand for target proteins for PROTAC, facilitating the development and design of PROTAC degraders for IRAK4. UR241-2 can be used in the research of acute myeloid leukemia.
-
Ginsenoside Rb1 (Standard)
0 ImagesSynonyms: Gypenoside III (Standard)Ginsenoside Rb1 (Standard) is the analytical standard of Ginsenoside Rb1. This product is intended for research and analytical applications. Ginsenoside Rb1, a main constituent of the root of Panax ginseng, inhibits Na+, K+-ATPase activity with an IC50 of 6.3±1.0 μM. Ginsenoside also inhibits IRAK-1 activation and phosphorylation of NF-κB p65 .
-
IRAK4 modulator-2
0 ImagesIRAK4 modulator-2 (Compound 5) is a selective dual Interleukin-1 Receptor Associated Kinase 4 (IRAK4) and IRAK1 inhibitor with IC50 values of 0.005 μM and 0.97 μM, erespectively. IRAK4 modulator-2 blocks IRAK-mediated signaling pathways (e.g., JAK-STAT, NF-κB pathways), reduces the production of pro-inflammatory cytokines (e.g., IL-1, TNF), and exerts anti-inflammatory activity. IRAK4 modulator-2 is promising for research of autoimmune diseases and inflammatory diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel disease.
